On October 27, 2026, NVO closed at $38.67, down $0.46 (-1.18%) from the October 26 close of $39.13, after printing a narrow $38.54-$39.025 range on 6.64 million shares - 0.60x the 20-day average of 11.05 million, 0.50x the 60-day average of 13.31 million and 0.71x the 10-day average of 9.36 million - the lightest participation in the entire 30-session window. The macro tape stayed constructive even as the stock fell: dropped another 4.73% to 17.52, the S&P 500 rose 0.60% to 7,722.60, the Nasdaq gained 1.18% and the Russell 2000 added 1.16%, while the 10-year Treasury yield ticked up to 4.993% from 4.986% and gold rallied 0.86% to $4,073.10. Technically, price held above the $38.435 for a ninth consecutive close but only by 0.61%, and it remains 5.54% below the $40.94 and 11.19% below the $43.544 , with the now 5.98% under a still-declining inside an intact death cross. The histogram stayed positive but decelerated for a third straight session to +0.30779 from +0.36128 on October 26 and the +0.41003 peak on October 22, slid to 43.23 from 46.39 and is the weakest reading since the 40.25 of October 19, and fell back to -293.13 million from -286.49 million, effectively erasing the prior session's improvement. Fundamentals remain the entire debate: 9.36x trailing and 11.24x forward earnings, 5.15x book, 0.518x sales, 1.545x , an 81.99% gross margin, 42.54% operating margin, 59.82% , $37.67 billion of free cash flow and a 4.59% dividend against 2.1% revenue growth, -20.6% earnings growth and a 4.37 . The forward sitting above the trailing is still the arithmetic of expected contraction, and current-quarter consensus of 4.62067 has been cut 4.25% in seven days and 9.56% in thirty days with two downward revisions and zero upward in each window, while next-year consensus of 22.88814 has risen 3.61% over seven days and 4.46% over thirty and now sits 2.25% above current-year consensus - the clearest evidence the street is underwriting a current-year earnings trough. Sell-side posture keeps softening: the mean target slipped to $44.84 (15.96% upside), the median to $41.82 (8.15%), and the street low to $39.52, now 2.21% above spot with the stock sitting below every published target, alongside 3 Buy / 10 Hold / 1 Sell versus 4 Buy / 10 Hold / 0 Sell three months ago. News flow has not refreshed (all items dated September 25) and remains mixed-bearish: the Nanexa delivery license worth up to $1.165 billion is a rational dosing-convenience play, but Lilly's Onswik approval and Viatris' generic Wegovy pen suit keep competitive and legal risk live, and there is no insider activity in the supplied lookback to arbitrate. The governing risk is the November 4 report, now 7 days away, into which near-term consensus is still falling while the stock rolls over from $39.13 to $38.67 on the thinnest volume of the month. We maintain HOLD across all horizons with the score easing to 46 from 48: nine closes above the , a still-positive histogram and a 4.59% dividend argue against selling into the print, while three sessions of histogram deceleration, a falling and , estimate cuts, a forward above the trailing multiple and a binary event 7 days out argue against paying up.
投资判断
实时价格
$38.67
推荐分数
46%
46%
置信度
58%
58%
各期限展望
1个月
持有
短线
6个月
持有
中期
1年
持有
长期
核心催化
The November 4 earnings report is the highest-probability catalyst for a move greater than 5%: it is 7 days away, current-quarter consensus has been cut 9.56% over 30 days and 4.25% in just the last week, the street-low target sits only 2.21% above spot, and the tape has compressed into a 34.0% six-week contraction on 0.50x 60-day volume - an earnings gap would resolve that compression decisively in one direction regardless of which way it breaks.
稳定性分类Balanced Growth组合角色Core Growth回撤风险High风险画像ModerateGLP-1 Competitive PressureEarnings Event Risk Nov 4Death Cross Intact Below EMA50Estimate Cuts Into the PrintDeep-Value Quality Pharma Multiple4.59% Covered DividendLowest Volume Of The WindowMACD Histogram Decelerating10Y Yield at 4.99%Viatris Patent SuitVIX Down to 17.52
决策工作台
价格地图
60日设置
价格轨道
$38.67
止损
当前
$36
$40
$43
$46
止损位
$37.40
买入
$38.00 - $38.70
止盈
$40.94 - $44.84
风险/回报
4.8x
有吸引力
到止损下行
-3.3%
到止盈上行
+16.0%
仓位提示
Use no more than half normal size into the November 4 report: at 17.52 is mid-band Neutral but the 10-year Treasury yield at 4.993% is still restrictive, 20-day realized volatility is 19.59%, and the stock is 7 days from a binary event while trading 5.54% below the inside a death cross on 0.50x 60-day volume. The October 27 close of $38.67 is inside the $38.00-$38.70 accumulation band, so scale rather than chase; add the second half only after a volume-confirmed close above the $40.94 .
投资逻辑快照
什么情况涨
At $38.67 NVO trades at 9.36x trailing and 11.24x forward earnings, 0.518x sales, 1.545x and 5.15x book while still generating an 81.99% gross margin, a 42.54% operating margin, 59.82% , $131.88 billion of operating cash flow and $37.67 billion of free cash flow, with a 4.59% dividend covered at a 45.09% payout and a 22.08% FCF yield that is extraordinary for a top-tier pharma franchise. Next-year consensus has risen 3.61% in the past week and 4.46% in the past month to 22.88814 and now sits 2.25% above current-year consensus, the clearest sign the sell-side expects this year to mark the trough, while Q2 2026 beat by 24.0%. The tape has not broken: October 27 was the ninth consecutive close above the $38.435 , the histogram has been positive for fourteen straight sessions, the closing higher-lows sequence from $37.32 to $38.06 to $38.42 is intact, and price sits 10.11% above the 52-week low. Macro turned more helpful with down 4.73% to 17.52 and the Nasdaq up 1.18% on the same day NVO fell, so the weakness is issuer-specific rather than systematic. Measured against the prior plan, the $38.42-$39.25 entry zone was reached again on October 27 (low $38.54, close $38.67), the $41.03-$45.03 exit zone was never approached and the $37.45 stop was never threatened, so the thesis remains live with price still above its 20-day average and 5.54% below the first real resistance.
什么情况跌
The cheapness may still be a value trap: revenue growth is 2.1% and earnings are contracting 20.6%, the forward of 11.24x sits above the trailing 9.36x, and the of 4.37 is nearly three times the 1.5x growth threshold. Current-quarter consensus has fallen 4.25% in seven days and 9.56% in thirty with two downward revisions and zero upward in each window, next-quarter consensus has dropped 5.61% in a week to 4.308 and now sits below the current quarter, BMO cut its target to $40 on October 12, Morgan Stanley is Underweight at $40, and the $39.52 street low now sits 2.21% ABOVE a $38.67 spot - the entire published target range has flipped above the market price, which typically means analysts are lagging the tape rather than defending it, and there is no margin of safety left in the distribution. The 22.08% FCF yield and 1.545x are so far outside normal large-cap pharma ranges that they should be treated as suspect until period and ADR/currency basis are validated, and net debt of $95.14 billion (-55.77% of market capitalization) with current/quick ratios of 0.87/0.64 leaves limited flexibility. Most importantly, the stock is leaking: October 27 fell 1.18% to $38.67 on 6.64 million shares - 0.60x the 20-day average and 0.50x the 60-day average, the lightest session of the window - the histogram has decelerated three straight sessions to +0.30779 from the +0.41003 peak, fell to 43.23 and has never cleared 50 in thirty sessions, intraday lows have started stepping down again ($38.75 to $38.67 to $38.54), and price remains 5.54% below the and 11.19% below a declining with the line negative at -0.5684. Short interest at just 1.00% of float with a 2.34 short ratio means there is no squeeze fuel, and a binary earnings event is 7 days away into a still-falling bar.
A daily close below $37.90 (the October 13-14 lows of $37.98/$37.90) would break the higher-lows sequence that underpins the entire basing thesis, and a close below the $36.85 October 5-6 shelf on volume above the 11.05 million 20-day average would confirm it and require exiting the position, with $35.12 (the 52-week low) as the final reference; conversely, a post-earnings failure that closes back below the $38.435 after the November 4 print would signal that the October basing attempt was a false move and that the death-cross downtrend has resumed.
Estimate and execution risk: current-quarter consensus has fallen 9.56% over 30 days and 4.25% in the last week to 4.62067 with zero upward revisions, next-quarter consensus has dropped 5.61% in a week to 4.308 from 4.564 and now sits below the current quarter, and current-year consensus is down 3.66% to 22.38512; if oral Wegovy uptake or U.S. pricing continues to disappoint, the newly lowered bar can still be missed on November 4, only 7 days away.
Competitive and legal risk: semaglutide-based medicines generated nearly $31 billion last year per the supplied article, Lilly now has a fourth global approval for once-weekly Onswik directly competing with Awiqli, Viatris is litigating Wegovy pen-administration patents in Delaware, and the Nanexa program could consume up to EUR 1.165 billion ($1.3 billion) of capital with no near-term revenue contribution.
Balance-sheet, event and macro risk: net debt is roughly $95.14 billion (-55.77% of market capitalization), current and quick ratios are 0.87 and 0.64 with cash covering only 0.32x of debt, 20-day realized volatility is 19.59% with at 2.11% of price, earnings are only 7 days away, and the 10-year Treasury yield at 4.993% remains high enough that a move back above 20 or a renewed rise in yields would compress multiples further regardless of NVO's already-low absolute valuation - while short interest at just 1.00% of float removes any squeeze cushion.
接下来关注
下一次财报：2026年11月4日
The November 4 earnings report is the highest-probability catalyst for a move greater than 5%: it is 7 days away, current-quarter consensus has been cut 9.56% over 30 days and 4.25% in just the last week, the street-low target sits only 2.21% above spot, and the tape has compressed into a 34.0% six-week contraction on 0.50x 60-day volume - an earnings gap would resolve that compression decisively in one direction regardless of which way it breaks.
信号仪表盘
决策输入
6 个信号
基本面
16.0%
距分析师均值目标空间
At $38.67, NVO trades at 9.36x trailing earnings, 11.24x forward earnings, 5.15x book, 0.518x sales and 1.545x against a $170.61 billion market capitalization and a $268.41 billion enterprise value. The absolute multiples are extraordinarily low for a franchise earning an 81.99% gross margin and paying a 4.59% covered dividend, but the forward (11.24x) sitting ABOVE the trailing (9.36x) is the arithmetic signature of expected earnings contraction rather than cheapness - current-quarter consensus has been cut 9.56% over 30 days to 4.62067 and current-year consensus to 22.38512. The of 4.37 is nearly three times the ~1.5x threshold normally used to justify a growth premium, so it must be read against revenue growth of 2.1% and earnings growth of -20.6%; on that combination the stock is a value stock with a growth multiple, not a growth stock at a value multiple. The 22.08% FCF yield, 1.545x and 0.518x sales are so far outside normal large-cap pharma ranges that they should be validated for period and ADR/currency basis before being capitalized - the estimate-revision series appearing to be DKK-denominated while the ADR trades in USD is exactly the kind of basis mismatch that would explain part of the gap (the 11.24x forward implies roughly $3.44 of forward at $38.67). No peer or historical multiple series is supplied, so a relative discount cannot be verified. On the supplied data NVO is cheap in absolute terms but not demonstrably undervalued given its earnings trajectory - either the market is mispricing a durable franchise or it is correctly discounting a structurally slowing GLP-1 business.
技术面
Neutral
趋势质量
At $38.67, price sits 0.61% above the $38.435 for a ninth consecutive close but remains 5.54% below the ($40.940) and 11.19% below the ($43.544). The is 5.98% below the after crossing under around September 18, so the death-cross structure still defines the primary trend as bearish, and both averages keep grinding lower ( $41.033 on October 26 to $40.940 on October 27; $43.593 to $43.544 over the same two sessions). The October 27 session broke the short-term higher-lows sequence on an intraday basis - the $38.54 low undercut the $38.75 (October 23) and $38.67 (October 26) lows - though the closing sequence from $37.32 (October 2) to $38.06 (October 13) to $38.42 (October 19) remains above the $38.435 . Price is 39.73% below the 52-week high of $64.16 and 10.11% above the 52-week low of $35.12, with a 52-week range position of 12.22%, so this is still a deeply damaged long-term chart attempting to base above the $36.85-$37.90 shelf.
财报
7天
Decelerating
Q2 2026 of $6.18 beat the $4.98333 consensus by 24.0%, but the beat did not arrest the revision cycle: current-quarter consensus has since fallen 9.56% over 30 days to 4.62067 and 4.25% in the last week with two downward revisions in each window and none upward, while next-quarter consensus has dropped to 4.308 from 4.564 a week ago. Only six quarters are supplied, so the average surprise of roughly +5.7% is dominated by that single outsized beat; the offsetting Q1 2026 miss of -4.75% plus the post-beat estimate cuts show limited forward visibility. The next test is the November 4 print, now 7 days away.
新闻
Mixed-Bearish
新闻基调
The November 4 earnings report is the highest-probability catalyst for a move greater than 5%: it is 7 days away, current-quarter consensus has been cut 9.56% over 30 days and 4.25% in just the last week, the street-low target sits only 2.21% above spot, and the tape has compressed into a 34.0% six-week contraction on 0.50x 60-day volume - an earnings gap would resolve that compression decisively in one direction regardless of which way it breaks.
宏观
Neutral
4.99% 10Y / 17.5 VIX
at 17.52 sits mid-band in the 15-20 Neutral zone after a second straight decline (-4.73%), so volatility itself is no longer a headwind, but a 4.993% 10-year yield still caps multiple expansion for a de-rated growth name, leaving NVO's falling estimate revisions and the November 4 print as the dominant swing factors.
稳定性
Balanced Growth
Core Growth
Novo Nordisk remains a top-tier pharmaceutical franchise on the income statement - 81.99% gross margin, 42.54% operating margin, 52.72% margin, 59.82% , $131.88 billion of operating cash flow, $37.67 billion of free cash flow and a 4.59% dividend covered at a 45.09% payout - and at 9.36x trailing and 11.24x forward earnings it belongs in a growth sleeve rather than a speculative bucket. But the equity has behaved nothing like its reported 0.384 beta: it sits 39.73% below its 52-week high, 11.19% below a declining inside a death cross, with 19.59% 20-day realized volatility and the 10-year Treasury at 4.993% compressing the multiple. Treat it as a moderate-size core growth holding that must be re-underwritten after the November 4 report, not as a defensive compounder and not as a full-size anchor; expect 40%+ peak-to-trough swings whenever the GLP-1 competitive narrative turns, with the 4.59% dividend providing only partial cushion during those episodes.
分析师目标区间
均值目标
$44.84
高低目标
$40 / $61
分析师中值目标
$41.82
共识区间
$40 - $61
— 位分析师
Mean
$40$45$61
市场共识
The $44.84 mean target implies 15.96% upside from $38.67, the $41.82 median implies 8.15%, the $39.52 street low implies only 2.21%, and the $61.44 high implies 58.9%. The distribution is heavily right-skewed and the low target now sits above the market price, meaning NVO trades below every published target - a configuration that usually signals analysts are behind the tape rather than cushioning it. The mix of 3 Buy, 10 Hold and 1 Sell is Hold-dominated and has deteriorated from 4 Buy / 10 Hold / 0 Sell three months ago, while both the BMO and Morgan Stanley $40 targets sit within roughly 3.4% of today's close. The analyst count for the mean target is null in the supplied data, so the mean should be treated as a wide-range aspiration rather than a floor.
筹码脉冲
内部人信号
Neutral
净偏向
No recent activity
内部人持股
0.0%
机构持股
9.8%
解读
With no reported insider buying or selling, insider behavior provides no confirmation of management's conviction in either direction ahead of the November 4 report, leaving the estimate-revision trend and the technical tape as the only real-time signals.
重要活动
No Form-4 transactions appear anywhere in the supplied lookback. Reported insider ownership is approximately 0.00% on the ADR line and almost certainly does not capture the full Danish share-class structure, so there is no basis to distinguish automatic 10b5-1 selling from discretionary activity, and no open-market purchase cluster to interpret.
市场背景
行业
Drug Manufacturers - General
Mixed-Bullish
情绪
14
跟踪股票
5
分组
industry
Drug Manufacturers - General 行业 当前情绪为 Mixed-Bullish，板块平均评分约 59 分，整体偏稳，且leadership is concentrated in LLY, JNJ, ABBV。
轮动线索
Drug Manufacturers - General 行业 组内评分变化不大，当前更像是存量博弈。
GLP-1 / Obesity and Cardiometabolic Drug Innovation
评分: -32
Mixed-Bearish
The GLP-1 and obesity theme remains one of the largest growth pools in healthcare, but capital continues to rotate toward Eli Lilly at Novo's expense: the supplied September 25 article notes LLY is up 10.5% year to date versus 13.7% for the industry, while NVO is down 7.29% year to date per the derived price metrics and 39.73% below its 52-week high. Novo's response is a convenience-driven pipeline strategy - the Nanexa PharmaShell license targets monthly-to-quarterly dosing across up to five cardiometabolic programs - but the payoff is years away, and Nanexa's own shares more than doubling on the news shows where the market assigned the value. The theme is active and Novo's relative position is weakening as Lilly adds a once-weekly basal insulin against Awiqli and Viatris litigates Wegovy pen patents; treat GLP-1 as a live theme with a clear issuer-specific bearish tilt for NVO until near-term estimate revisions stop falling.
The November 4 report is 7 days away while current-quarter estimates are still being cut and the stock has rolled back to $38.67, only 0.61% above its 20-day average, making the next week a referendum on whether Novo's lowered bar is finally low enough.
NVO is down 7.29% year to date while the September 25 article reported LLY up 10.5% year to date and the industry up 13.7% - evidence of intra-theme rotation toward Lilly, though no fund-flow series is supplied.
Nanexa shares more than doubled on the Novo license, showing investor appetite for long-acting delivery technology even as Novo's own equity de-rated and the deal remains pre-clinical optionality.
Lilly secured a fourth global approval for Onswik and added a once-weekly basal insulin that the article explicitly frames as direct competition to Novo's Awiqli, reinforcing the narrative that Lilly is winning the convenience race.
Long-Acting Injectable / Dosing-Convenience Race
评分: 25
Mixed-Bullish
Dosing frequency has become the next competitive axis in metabolic disease, and capital is paying up for the enabling technology rather than for the incumbent marketers: Nanexa's Stockholm-listed shares more than doubled on the Novo PharmaShell license, and Lilly's once-weekly Onswik approval cuts basal insulin injections from roughly 365 to 52 per year. Novo is participating as a payer of up to EUR 1.165 billion ($1.3 billion) rather than as the perceived owner of the technology, which keeps the theme bullish for delivery platforms and neutral-to-negative for Novo's own multiple until a candidate enters the clinic. The theme is strengthening on evidence rather than narrative - two concrete transactions in a single week - but the revenue impact for Novo sits years beyond the November 4 print.
Lilly's fourth global Onswik approval and Novo's up-to-$1.3 billion Nanexa license landed in the same week, crystallizing convenience as the axis on which the next leg of the obesity and diabetes market will be contested.
Nanexa's shares more than doubled in early Friday trading after the Novo license, a direct signal that the market is crediting the delivery-technology layer rather than the incumbent sponsor.
Onswik's U.S. approval followed regulatory clearances in the European Union, Mexico and Japan, giving Lilly a four-region once-weekly insulin franchise that the article explicitly frames as competing with Novo's Awiqli.
关键指标
23 项指标
市值
$170.61B
市盈率 (TTM)
9.4
远期市盈率
11.2
营收增速
2.1%
净资产收益率
59.8%
Beta 系数
0.38
完整指标集
另外 17 项指标
估值结构
估值倍数与现金流框架。
市销率
0.5
市净率
5.1
企业价值 / EBITDA
1.5
质量与资产负债表
利润率、杠杆与流动性。
毛利率
82.0%
营业利润率
42.5%
资产负债率
63.3
流动比率
0.87x
速动比率
0.64x
仓位与价格区间
空头仓位与52周区间位置。
流通盘空头占比
1.0%
空头回补天数
2.34x
52周最高
$64.16
52周最低
$35.12
距52周高点
-39.7%
距52周低点
10.1%
公司分类
板块与行业背景。
板块
Healthcare
行业
Drug Manufacturers - General
其他信号
自由现金流
$37673250816.00
详细分析
估值
At $38.67, NVO trades at 9.36x trailing earnings, 11.24x forward earnings, 5.15x book, 0.518x sales and 1.545x against a $170.61 billion market capitalization and a $268.41 billion enterprise value. The absolute multiples are extraordinarily low for a franchise earning an 81.99% gross margin and paying a 4.59% covered dividend, but the forward (11.24x) sitting ABOVE the trailing (9.36x) is the arithmetic signature of expected earnings contraction rather than cheapness - current-quarter consensus has been cut 9.56% over 30 days to 4.62067 and current-year consensus to 22.38512. The of 4.37 is nearly three times the ~1.5x threshold normally used to justify a growth premium, so it must be read against revenue growth of 2.1% and earnings growth of -20.6%; on that combination the stock is a value stock with a growth multiple, not a growth stock at a value multiple. The 22.08% FCF yield, 1.545x and 0.518x sales are so far outside normal large-cap pharma ranges that they should be validated for period and ADR/currency basis before being capitalized - the estimate-revision series appearing to be DKK-denominated while the ADR trades in USD is exactly the kind of basis mismatch that would explain part of the gap (the 11.24x forward implies roughly $3.44 of forward at $38.67). No peer or historical multiple series is supplied, so a relative discount cannot be verified. On the supplied data NVO is cheap in absolute terms but not demonstrably undervalued given its earnings trajectory - either the market is mispricing a durable franchise or it is correctly discounting a structurally slowing GLP-1 business.
资产负债表
Cash of $44.98 billion against total debt of $140.13 billion leaves net debt of approximately $95.14 billion, or -55.77% of market capitalization. Debt-to-equity of 63.33% (about 0.63x) is moderate, and operating cash flow of $131.88 billion produces an operating-cash-flow-to-debt ratio of 0.94x, so servicing capacity is solid. Free cash flow of $37.67 billion comfortably covers the 45.09% payout ratio behind the 4.59% dividend. The offsets are liquidity and disclosure: current and quick ratios of 0.87 and 0.64 are both below 1.0, cash covers only 0.32x of total debt, and free cash flow represents roughly 28.6% of operating cash flow - a conversion gap the supplied data does not explain. Debt maturity, currency mix and borrowing-cost detail are not supplied, which matters for a company carrying $140.13 billion of debt into a 4.993% 10-year yield environment.
增长
Revenue growth of 2.1% year over year against earnings growth of -20.6% is a sharply decelerating profile for a company still marketed as a high-growth GLP-1 franchise. Consensus current-quarter has fallen from 5.10933 to 4.62067 over 30 days (-9.56%) and from 4.8255 a week ago (-4.25%), while current-year is down 3.66% over 30 days to 22.38512 from 23.23517. Next-quarter at 4.308 is now 1.44% below its 30-days-ago level of 4.371 and 5.61% below the 4.564 of a week ago, and critically it sits below the current quarter's 4.62067 - the out-quarter curve is still bending downward. The one constructive signal is next-year consensus, which rose from 22.09162 a week ago to 22.88814 (+3.61%) and from 21.91143 thirty days ago (+4.46%), and now sits 2.25% above current-year consensus, implying the sell-side expects the trough this year with modest growth resuming afterward. Margin trend cannot be established because no margin time series is supplied, and no forward revenue growth estimate is provided.
生意质量
Gross margin of 81.99%, operating margin of 42.54%, margin of 52.72%, net profit margin of 35.35%, of 59.82% and of 18.73% place NVO in the top tier of pharmaceutical economics and reflect genuine pricing power on its existing semaglutide portfolio. Liquidity ratios below 1.0 (current 0.87, quick 0.64, cash-to-debt 0.32) are the main quality caveat, partly mitigated by $131.88 billion of operating cash flow and the 0.94x operating-cash-flow-to-debt ratio. Reported institutional ownership of 9.82% and insider ownership of roughly 0.00% on the ADR line almost certainly understate the true Danish share-class structure and should not be used as a governance read-through. Business quality supports a premium multiple in principle, but a 20.6% earnings decline and unresolved competitive uncertainty cap how much premium can be justified today - the franchise is elite, the current earnings arc is not.
资本配置
With $44.98 billion of cash against $140.13 billion of debt, the balance sheet is levered but well covered by $131.88 billion of operating cash flow and $37.67 billion of free cash flow. The 4.59% dividend at a 45.09% payout ratio looks sustainable on supplied free cash flow, making the payout a real component of total return while the equity attempts to re-rate. The Nanexa global license can total up to EUR 1.165 billion ($1.3 billion), including up to EUR 615 million in upfront, development and regulatory milestones plus low single-digit royalties, across as many as five peptide programs in obesity, type 2 diabetes and other cardiometabolic disease - strategically logical for dosing-frequency defense but an early-stage commitment with no near-term earnings contribution, and the fact that Nanexa's own shares more than doubled on the announcement shows where the market assigned the value. Shares outstanding are 3.337 billion against a float of 3.173 billion, with no share-count trend or buyback data supplied, so per-share accretion or dilution cannot be assessed.
预期修正
Near-term estimate momentum is still deteriorating even as the shape of the curve improves at the far end. Current-quarter consensus fell to 4.62067 from 4.8255 seven days ago and 5.10933 thirty days ago (-4.25% over seven days, -9.56% over thirty, and -9.98% versus the 5.133 of sixty days ago). Revision breadth confirms the damage: two downward current-quarter revisions in the last seven days and two in the last thirty with zero upward in either window, and two downward current-year revisions against one upward. The +1q revision-count field shows two upward revisions in each window even though the point estimate fell to 4.308 from 4.564, so counts and point estimates disagree and the point-estimate trend should carry more weight. Offsetting this, next-year consensus rose to 22.88814 from 22.09162 a week ago (+3.61%) and from 21.91143 thirty days ago (+4.46%), with two upward revisions versus one downward in each window, and it now sits 2.25% above current-year consensus - the market is beginning to price a current-year earnings trough. Sell-side posture is quietly worsening: BMO Capital cut its target from $47 to $40 on October 12 while maintaining Market Perform, Morgan Stanley moved to Underweight from Equal-Weight on September 11 with a $40 target, and the recommendation tally drifted from 4 Buy / 10 Hold / 0 Sell three months ago to 3 Buy / 10 Hold / 1 Sell today. The aggregate field reports zero formal upgrades or downgrades over 90 days even though the latest-actions detail records both a downgrade and a target cut, so the aggregate understates the actual drift.